rotavirus vaccines
Long term impact of self financed rotavirus vaccines on rotavirus associated hospitalizations and costs in the Valencia Region, Spain
... Two rotavirus vaccines, the monovalent (RV1; Rotarix®, GSK) and the pentavalent (RV5; RotaTeq®, Merck), were licensed in Spain in August 2006 and January 2007, re- ...of rotavirus vaccination in ...
8
A Multi-Center, Qualitative Assessment of Pediatrician and Maternal Perspectives on Rotavirus Vaccines and the Detection of Porcine circovirus
... Rotavirus vaccines are oral, live, attenuated vaccines that have been shown in large clinical trials and through post-licensure surveillance to be safe and highly effective in protecting children ...
11
Efficacy, safety and effectiveness of licensed rotavirus vaccines: a systematic review and meta-analysis for Latin America and the Caribbean
... licensed rotavirus vaccine was RotaShield™ (Wyeth Laboratories, ...severe rotavirus diarrhea in randomized clinical trials [7 – ...new rotavirus vaccines with different antigen compositions ...
12
Effectiveness of rotavirus vaccines, licensed but not funded, against rotavirus hospitalizations in the Valencia Region, Spain
... between rotavirus and non-rotavirus vaccinees for having received at least one vaccine in a private center, and for having health cover- age at the time of data extraction, could reflect in part the ...
9
Intussusception After Rotavirus Vaccines Reported to US VAERS, 2006–2012
... BACKGROUND: In 2006 and 2008, 2 new rotavirus vaccines (RotaTeq [RV5] and Rotarix [RV1]) were introduced in the United States. METHODS: We assessed intussusception events reported to the Vac- cine Adverse ...
10
Population effectiveness of the pentavalent and monovalent rotavirus vaccines: a systematic review and meta analysis of observational studies
... of rotavirus infection, and treatment of RVGE is limited to rehydration ther- apy, immunisation of infants is considered the best op- tion for control of the global burden of rotavirus ...oral ...
19
Effectiveness of rotavirus vaccines against hospitalisations in Japan
... the rotavirus antigen positivity as bi- nary outcome after matching the age categories of cases with those of test-negative controls and including vac- cination status (at least one dose), residence (Yuri-Honjo ...
7
Predictors of Uptake and Timeliness of Newly Introduced Pneumococcal and Rotavirus Vaccines, and of Measles Vaccine in Rural Malawi: A Population Cohort Study
... of vaccines but delays in schedule ...new vaccines in Malawi [7], we analysed data from a population-based birth cohort study to investigate factors affecting vacci- nation coverage and timeliness in ...
15
Magnitude of Serum and Intestinal Antibody Responses Induced by Sequential Replicating and Nonreplicating Rotavirus Vaccines in Gnotobiotic Pigs and Correlation with Protection
... three oral doses of attenuated HRV (AttHRV) vaccine alone (AttHRV1x and AttHRV3x, respectively) or i.n. with a non- replicating RV VLP vaccine alone or after vaccination with a prime-boost sequential vaccine regimen ...
9
An Indian Perspective of Some Recent Developments in Polio, DPT, Zika and Rotavirus Vaccines
... 15. Gerald TK, Fontaine O, Bhargava A, Cynthia BP, Zulfiqar A, et al. Diarrheal Diseases. In: Jamison DT, Breman JG, Measham AR, Alleyne G, Claeson M, Evans DB, editors. Disease Control Priorities in Developing ...
11
Safety and Efficacy of High-dose Rhesus-Human Reassortant Rotavirus Vaccines—Report of the National Multicenter Trial
... lent RRV-S1 and RRV-TV rhesus human reassortant vaccines.. METhODS.[r] ...
9
Rotavirus Vaccines and Health Care Utilization for Diarrhea in the United States (2007–2011)
... compared rotavirus-coded hospitalization and diarrhea-associated health care utili- zation rates during each of the post- vaccine years 2007 – 2011 (July – June) with the annual mean rates during the 5-year ...
11
Effectiveness of rotavirus vaccines against rotavirus infection and hospitalization in Latin America: systematic review and meta-analysis
... severe rotavirus-diarrhoea ranged from 85 to 98 % and rotavirus-associated hospitalisation ranged from 85 to 94 % [4, ...the vaccines to reduce infections was not reported ...2 Rotavirus G and ...
12
Decision Making Amplification Under Uncertainty: An Exploratory Study of Behavioral Similarity and Intelligent Decision Support Systems
... The rotavirus vaccines have a unique age restriction compared to other recommended vaccines for routine ...Few vaccines have an upper age limit of such a short time span as the RV ...
41
Rotavirus symptomatic infection among unvaccinated and vaccinated children in Valencia, Spain
... oral rotavirus vaccines have been marketed worldwide: the monovalent Rotarix® (GSK Biologicals, Rixensart, Belgium), an attenuated hu- man G1P[8] vaccine, and the pentavalent bovine-human mono-reassortant ...
10
A Survey of Pediatricians on the Reintroduction of a Rotavirus Vaccine
... about rotavirus disease in the United States and developing world, past and anticipated uses of a rotavirus vaccine, and perceived advantages and barriers to reintroducing a rotavirus ...new ...
7
Molecular characterization of rotavirus isolates from select Canadian pediatric hospitals
... oral rotavirus vaccines were licensed in ...bovine rotavirus WC3 strain as a backbone, and each of the 5 vaccine strains contains one serotype of the human outer capsid proteins (G1, G2, G3, G4, or ...
9
Childhood intussusception in Uzbekistan: Analysis of retrospective surveillance data
... In conclusion, our study provides useful information on the incidence and epidemiology of childhood IS in Uzbekistan. Because we did not conduct prospective surveillance in the current study, additional research using an ...
6
Why does the world need another rotavirus vaccine?
... recommend rotavirus vaccine introduction in regions of the world where the clinical effi cacy of the vaccines have been demonstrated, ie, essentially in Latin America and Europe; secondly, the WHO approval ...
16
Vaccines for preventing rotavirus diarrhoea: vaccines in use (Review)
... that rotavirus vaccines must demonstrate protective efficacy against all of the major circulating strain types (de Quadros 2004) as well as new strains that will continue to emerge (Gentsch ...’monovalent’ ...
280